EGFR and non-small cell lung carcinoma: The pooled analysis revealed no significant difference in the OS for older adult patients with advanced EGFR-mutated NSCLC who were treated with different EGFR TKIs (gefitinib, erlotinib, afatinib, dacomitinib and osimertinib) (HR = 0.989, 95% CI: 0.796 to 1.229; p = 0.921; Figure 4).